A case series of BRAF V600E inhibitor (PLX4032) related cutaneous eruptions in metastatic melanoma

被引：0
|
作者：
Sinha, R. [1 ]
Fearfield, L. [2 ]
Larkin, J. [1 ]
机构：
[1] Chelsea & Westminster Hosp NHS Fdn Trust, London, England
[2] Royal Marsden NHS Fdn Trust, London, England
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2011年 / 165卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：19 / 19
页数：1
相关论文
共 50 条
  • [1] Multiple murine BRaf V600E melanoma cell lines with sensitivity to PLX4032
    Jenkins, Molly H.
    Steinberg, Shannon M.
    Alexander, Matthew P.
    Fisher, Jan L.
    Ernstoff, Marc S.
    Turk, Mary Jo
    Mullins, David W.
    Brinckerhoff, Constance E.
    PIGMENT CELL & MELANOMA RESEARCH, 2014, 27 (03) : 495 - 501
  • [2] Antitumor activity of PLX4032, a novel B-Raf V600E inhibitor
    Lee, J. T.
    Kong, J.
    Smalley, K.
    Tsai, J.
    Cho, H.
    Bollag, G.
    Herlyn, M.
    EJC SUPPLEMENTS, 2006, 4 (12): : 172 - 173
  • [3] Vemurafenib (PLX4032): An Orally Available Inhibitor of Mutated BRAF for the Treatment of Metastatic Melanoma
    Heakal, Yasser
    Kester, Mark
    Savage, Scott
    ANNALS OF PHARMACOTHERAPY, 2011, 45 (11) : 1399 - 1405
  • [4] The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner
    Joseph, Eric W.
    Pratilas, Christine A.
    Poulikakos, Poulikos I.
    Tadi, Madhavi
    Wang, Weiqing
    Taylor, Barry S.
    Halilovic, Ensar
    Persaud, Yogindra
    Xing, Feng
    Viale, Agnes
    Tsai, James
    Chapman, Paul B.
    Bollag, Gideon
    Solit, David B.
    Rosen, Neal
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2010, 107 (33) : 14903 - 14908
  • [5] An in-frame deletion in the N-terminal regulatory domain of BRAF(V600E) causes resistance to the RAF inhibitor PLX4032
    Poulikakos, Poulikos I.
    Persaud, Yogindra
    Gabay, May Tal
    Janakiraman, Manickam
    Joseph, Eric W.
    Pratilas, Christine A.
    Chapman, Paul B.
    Rosen, Neal
    Solit, David B.
    CANCER RESEARCH, 2011, 71
  • [6] PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas
    Lee, John T.
    Li, Ling
    Brafford, Patricia A.
    van den Eijnden, Marcia
    Halloran, Molly B.
    Sproesser, Katrin
    Haass, Nikolas K.
    Smalley, Keiran S. M.
    Tsai, James
    Bollag, Gideon
    Herlyn, Meenhard
    PIGMENT CELL & MELANOMA RESEARCH, 2010, 23 (06) : 820 - 827
  • [7] Phase I study of PLX4032: Proof of concept for V600E BRAF mutation as a therapeutic target in human cancer
    Flaherty, K.
    Puzanov, I.
    Sosman, J.
    Kim, K.
    Ribas, A.
    McArthur, G.
    Lee, R. J.
    Grippo, J. F.
    Nolop, K.
    Chapman, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [8] Constitutively active RAS and MEK confer resistance to PLX4032 in BRAF-V600E human melanoma cells
    Somers-Edgar, Tiffany J.
    Ferrao, Petranel
    Callahan, Jason
    Bollag, Gideon
    Hicks, Rod
    Johnstone, Ricky
    McArthur, Grant A.
    CANCER RESEARCH, 2011, 71
  • [9] The analytic performance of a real-time PCR-based assay for the BRAF V600E mutation used as the companion diagnostic test for the novel BRAF inhibitor RG7204 (PLX4032) in metastatic melanoma
    Halait, Harkanwal
    DeMartin, Kelli
    Shah, Sweta
    Soviero, Stephen
    Langland, Rachel
    Cheng, Suzanne
    Hillman, Grantland
    Wu, Lin
    Lawrence, Jeffrey
    CANCER RESEARCH, 2011, 71
  • [10] PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF(WT) melanoma cells (vol 23, pg 190, 2010)
    Halaban, R.
    Zhang, W.
    Bacchiocchi, A.
    Cheng, E.
    Parisi, F.
    Ariyan, S.
    Krauthammer, M.
    McCusker, J. P.
    Kluger, Y.
    Sznol, M.
    PIGMENT CELL & MELANOMA RESEARCH, 2012, 25 (03) : 402 - 402
12345